The puffer fish (Fugu rubripes) has a compact genome of 400 Mbp which is ∼7.5-fold smaller than the human genome. It contains a similar number of genes but is deficient in intergenic, intronic and dispersed repetitive sequences. Fugu is becoming established as the model vertebrate genome for the identification and characterisation of novel human genes and conserved regulatory sequences. It has also been proposed that Fugu genes may provide natural mini-genes for the production of transgenic mice. We have used the Fugu homologue of the Huntington's disease (HD) gene to test this possibility. The human and Fugu HD genes cover 170 kb and 23 kb respectively and have previously been sequenced in their entirety. In Fugu tissue, the Fugu HD gene was found to be expressed as predicted from the gene sequence but three differentially spliced forms were also detected. Despite the absence of conserved promoter sequences, the Fugu promoter was found to be functional in mouse cells. We have generated mice transgenic for the Fugu HD gene and conducted a detailed expression analysis across the entire 10 kb transcript. This revealed the presence of many aberrant splice forms which would be incompatible with the production of the Fugu huntingtin protein. The Fugu HD gene is incorrectly processed in mouse cells both in vitro and in vivo which sheds doubt on the usefulness of Fugu genes for transgenesis.
INTRODUCTION
Brenner et al. have recently proposed that the pufferfish (Fugu rubripes) provides an ideal model vertebrate for the discovery of human genes (1) . A random sequencing approach combined with gene probing was used to demonstrate that the organism has a compact genome with a haploid content of 400 Mb (7.5-fold smaller than the human genome). This analysis predicted an equivalent amount of coding DNA (corresponding to a similar number of genes), implying that the smaller size is due to a reduction in intronic and intergenic sequences. All forms of repetitive DNA make up <10% of the Fugu genome and there are no abundant classes of dispersed repeats. It is anticipated that a comparison of the Fugu and human genomes would maximise the evolutionary distance between two vertebrate genomes and that conserved sequences are likely to have a functional or structural importance (1) .
A more detailed characterisation of the Fugu genome is emerging from the initial comparative sequencing projects (2,3). Sequence comparison has been possible across the entire gene in the case of Huntington's disease (HD) (4), glucose-6-phosphate dehydrogenase (G6PD) (5) and tuberous sclerosis 2 (TSC2) (6) . The intron-exon organisation was found to be very well conserved with a complete conservation of intron-exon boundaries. In the case of TSC2 the intron-exon structure as predicted in Fugu helped to identify the novel alternatively spliced exon 31 in humans and the same pattern of alternative splicing was observed for exons 25 and 31 between the human and Fugu TSC2 genes (6) . The Fugu gene was smaller in all cases: by 2.5-fold for TSC2, 4-fold for G6PD and 7.5-fold for HD as a consequence of smaller intron size. However, there are notable exceptions to this rule, e.g., the dopamine receptor homologues in which the intron sizes are comparable between human and Fugu, the significance of which is unknown (7) . The Fugu genome is amenable to the study of gene families, which because of the small intron size can be isolated readily from genomic DNA by PCR, e.g. the actin genes (8) and Hox clusters (9) . Although the size of the conserved linkage groups between Fugu and human have not yet been determined, short-range conserved synteny has been established for a number of adjacent Fugu genes (2) . With a predicted gene density of one gene per 7 kb, the Fugu genome will clearly be important in the identification of novel genes.
Comparative sequence analysis between the Fugu and mammalian genomes should also be useful in pinpointing the position of sequences important in the control of gene expression. This approach has been successful in the discovery of poorly mapped enhancers in the Hox-b cluster (10) . The hox genes are tightly regulated and it is not surprising that the control elements are highly conserved. It is difficult to predict the degree of similarity between the factors that control ubiquitously expressed genes, and *To whom correspondence should be addressed. Tel: +44 171 955 2505; Fax: +44 171 955 4444; Email: g.bates@umds.ac.uk indeed Fugu housekeeping genes do not possess classical CpG islands. The CpG content of the Fugu genome (0.5 of that expected) lies between human (0.2 of that expected) and Drosophila (expected CpG content). Generally, the CpG content does not appear to be raised at the 5′ end of Fugu genes, and, although there are isolated regions throughout genes that have raised CpG values, these may reflect the codon bias in the GC rich exons (2, 11) .
The HD gene was one of the first genes for which a sequence comparison between human and Fugu homologues has been conducted (4). The human gene covers 170 kb and contains 67 exons (12) . The HD mutation is a CAG/polyglutamine expansion located in exon 1 (13) with normal and expanded allele sizes of 6-39 and 35-180 respectively. Two ubiquitously expressed transcripts of 10 366 bp and 13 711 bp have been identified arising through differential polyadenylation (14) and there is no hard evidence for alternative splicing. The transcript is expressed in every foetal and adult tissue examined (15) (16) (17) and Western analysis has shown the expanded CAG repeats to be translated (18) (19) (20) . The normal function of the protein is not known although, within neurons, immunocytochemistry suggests a cytoplasmic localisation and a possible association with synaptic vesicles (19, 21, 22) . The mutation causes a late onset neurodegenerative disease and is thought to act by a dominant gain of function. This is supported by the isolation of a monoclonal antibody (1C2) that specifically recognises polyglutamine expansions, consistent with a conformational change occurring once the expansion has crossed a size threshold (23) . Similarly, mice that are transgenic for the HD mutation (24) develop a progressive neurological phenotype, the cellular basis of which has been shown to be the formation of novel neuronal intranuclear inclusions that are immunoreactive for antibodies directed against the transgene protein (25).
The Fugu homologue of the HD gene (FrHD) covers 23 kb, which is 7.4-fold smaller than the human gene (170 kb) and is consistent with the relative genome sizes. All 67 exons and the exon-intron boundaries are conserved and the coding region is 69% identical at the nucleotide level (4) . The exons are of a comparable size to the human exons but the intronic regions are considerably smaller, ranging from 47 to 1476 bp in Fugu compared with 131 to 12 286 bp in human. In four cases the Fugu introns were larger than the corresponding human introns which may imply an unknown functional constraint. The glutamine repeat is also conserved and encoded by (CAG) 2 (CAA) 2 compared with (CAG) 2 CAA(CAG) 4 in mouse (26, 27) , (CAG) 2 CAA(CAG) 5 in the rat (28) and (CAG) CAACAG in humans (13) . Comparison of the coding sequences uncovered five regions with >80% identity at the nucleotide level, including the N-terminus containing the polyglutamine repeat. However, this degree of homology was insufficient to pinpoint functional domains. The 5′ and 3′ untranslated regions were less well conserved. The Fugu gene has three potential polyadenylation signals suggesting that, as in humans, differential polyadenylation could generate more than one transcript.
One possible further application of Fugu genes is their use in transgenic mouse assays (11) . DNA for transgenesis can be introduced either as a cDNA construct under the control of an appropriate promoter, or as a genomic fragment including endogenous control elements. Transgenes introduced as cDNAs are often poorly expressed or inappropriately regulated and lack sequences needed to generate alternatively spliced or differentially polyadenylated transcripts. However, the large size of many human genes necessitates that they be manipulated and introduced into the mouse germ line in the form of a YAC clone (29) . Preparation of these constructs often requires a number of sequential homologous recombination steps and care must be taken in handling these large DNA molecules. Fugu genes may provide natural minigenes which could be introduced in the form of a cosmid clone making the preparation and manipulation of the constructs correspondingly more straightforward whilst retaining many of the advantages of working with a genomic clone. We set out to use the well characterised Fugu HD gene (FrHD) to test the use of Fugu genes for murine transgenesis. 
RESULTS

Expression profile of the FrHD gene
The human and mouse HD genes are both widely expressed in brain and peripheral tissues. Prior to the analysis of the FrHD gene in mouse we set out to ensure that the processed mRNA in Fugu tissues was as predicted from the sequence comparison of the genomic Fugu sequence with that of the human and mouse cDNAs. By Northern analysis, the gene was found to be expressed in all tissues tested except muscle (Fig. 1a) , although a transcript could be identified in muscle by the more sensitive RT-PCR (see below). The Northern signal appeared as a somewhat diffuse doublet of ∼10 kb. To carry out a more detailed analysis of the FrHD mRNA, we designed primer sets along the entire length of the coding sequence (Table 1) . RT-PCR amplification generated a product of the size predicted by the genomic sequence and conserved splice junctions for all but three regions of the mRNA. Aberrant products were obtained with primers that amplified exons 1-8, 8-13 and 63-67. Amplification of exons 1-8 generated two products, one of the expected size (803 bp) and a second 81 bp larger. Amplification of exons 8-13 produced a 840 bp product of the expected size and an additional larger product of 869 bp. Amplification of exons 63-67 produced two products in brain, one of the predicted size (779 bp) and a larger product of 890 bp, with only the larger product being detected in the other tissues. As an initial approach to determine whether aberrant bands were artifactual, the PCR products were hybridised with an appropriate internal oligonucleotide (Fig. 1b) . The additional splice products were sequenced and the alternatively spliced isoforms were found to include: the retention of intron 7 (81 bp), the removal of exon 10 (48 bp) and retention of intron 11 (77 bp), and the use of an internal acceptor site in intron 63 to 'splice in' 111 bp of intron 63. Correspondingly, a branch site sequence (CGCTGAC) was identified 28 nt before the internal splice acceptor sequence. The addition of intron 7 and the 3′ end of intron 63 maintains the open reading frame of the mRNA. However, splicing of exon 9 to exon 11 shifts the reading frame leading to two termination codons in the retained intron 11 sequence. The genomic sequence of the FrHD gene predicted that there were three possible polyadenylation signals. We performed 3′ RACE to identify the presence of different polyadenylated mRNA forms in Fugu RNA prepared from a number of Fugu tissues. In all cases, PCR products corresponding to the use of the polyadenylation signals predicted at positions 26080 (AGTAAA) and 27410 (ATTAAA) were present, but that corresponding to 26884 (AGTAAA) was not found (Fig. 1c) . This would suggest two alternative 3′ untranslated regions of 191 and 1521 bp respectively. In brain an additional 3′ RACE product was consistently observed which could be explained if the sequence AACAAA acts as a polyadenylation signal 165 bp 3′ to 26080. The use of two major polyadenylation sites is consistent with the observation of a doublet on the Northern blot. The diffuse nature of the Northern blot signals could be explained further by the alternative splice forms described above.
The FrHD gene is expressed from its own promoter in mouse cells
Comparative sequence analysis of the promoter regions of the Fugu and human HD genes did not reveal any similar sequence motifs. In addition, the GC content was not raised. Therefore, before generating constructs for transgenesis it was important to determine whether the Fugu promoter was functional in mouse cells. To test this, a 30 kb EagI fragment (Fig. 2) , was co-transfected into mouse L cells with pKJ1 plasmid containing a neo resistance gene. More than 27 kb of this fragment has been sequenced and it contains the entire coding region with 2.84 kb of upstream and 4 kb of downstream sequences. Approximately 80 neo resistant colonies were established as stable transformants, all of which were found also to contain the FrHD gene. Southern analysis identified those cell lines containing an intact gene and promoter region (data not shown). Ten lines were chosen for expression analysis. Using primers specific to exons 12 and 14 that discriminate between the mouse and Fugu RNA, RT-PCR indicated the presence of a correctly spliced mRNA product in all lines (data not shown). It was therefore clear that the Fugu promoter is functional in mouse cells.
Generation of mice transgenic for FrHD
The 30 kb EagI fragment containing the FrHD gene was used to generate transgenic mice by standard procedures. Two founders were recovered from 51 newborns, FrHD43 (male) and FrHD46 (female), both of which transmitted the transgene to their offspring. The genomic structure of the integration sites was determined by Southern analysis (Fig. 3) . HindIII digestion of FrHD46 DNA indicated that this line contained a single truncated copy of the transgene extending from the 5′ end of the gene and containing 26 exons (as determined by PCR). Digestion of FrHD43 DNA with ScaI, which has a unique site within the microinjection fragment, indicated that the FrHD43 line contained three or four tandem copies of the transgene (as estimated from band intensities).
Expression of the FrHD gene in mouse in vivo and in vitro
As only one transgenic founder containing intact copies of the FrHD gene was recovered, the expression analysis was performed on this transgenic line and two of the L-cell transfectants in parallel. The primers described in Table 1 had been designed to discriminate between the Fugu and mouse transcripts, thereby specifically amplifying the Fugu sequences. The structure of the Fugu mRNA in mouse was analysed by RT-PCR using primers spaced along the transcript, and by 3′ RACE. No difference in the pattern of RT-PCR products was identified between brain, liver and kidney. Hybridisation of internal oligonucleotides to RT-PCR products was used to indicate specific amplification products. This analysis is summarised in Table 2 and examples of the RT-PCR amplification products are provided in Figure 4a . RT-PCR indicated that the only portion of the FrHD mRNA to have been correctly processed was that lying between exons 30-35 and 38-48. The analysis was extended to include more primers in an attempt to narrow further the localisation of the aberrant splicing events. However, this approach must be treated with caution. An aberrant product may not be detected, either because the incorrect splicing is not occurring in the part of the amplification product under further analysis, or because the region containing the primer sequence has been incorrectly 'spliced out'. Various FrHD cDNA probes were used against Northern panels containing Fugu RNA and RNA from the transgene and transfectants. Whilst discrete bands were present in the Fugu tissue RNA, a high molecular weight smear was detected in the transgene or transfectant RNA (Fig. 4b) , consistent with the presence of a broad range of incorrectly processed transcripts. 
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A sequence analysis of the aberrant splice products was initiated. The sequence of the RT-PCR product from exons 1-8 showed that intron 7 (81 bp) had been retained. This was identical to one of the aberrant splice forms identified in the Fugu tissues, and it maintains the reading frame of the message. The 3′ 84 bp of intron 4 was also found arising from the presence of a possible branch site sequence (CATTTAT) 20 nucleotides prior to an internal splice acceptor site (Y 6 AG). This aberrant splice product contained four in-frame stop codons and would be incompatible with the production of a full length FrHD protein. All of the transgene mouse tissues tested and the L-cell transfectants showed no evidence of a correctly spliced product that did not contain the in-frame stop codons in intron 4. Sequencing of the many other aberrant splice forms was not pursued once this result had been obtained.
Differential polyadenylation was found to originate from the polyadenylation signals predicted at positions 26080 (AGTAAA) and 27410 (ATTAAA) in the genomic sequence. Therefore the same polyadenylation signals were used in both the Fugu and mouse cells. However, in mouse there was no evidence of the brain-specific product detected in Fugu (Fig. 4c) .
DISCUSSION
Comparative sequencing projects between the genomes of human and Fugu rubripes are providing increasing evidence that Fugu represents a good model genome for the identification of human genes and control elements (2, 3) . Human and Fugu represent the maximum evolutionary distance between two vertebrates and conserved sequences are expected to have a functional importance. The major attraction of the Fugu genome is its relatively compact size of ∼7.5 fold smaller than the human genome (1). This has arisen by the loss of intronic and intergenic sequences, the selective pressure for which is unknown. It has been suggested that in cases of very large human genes, these natural Fugu minigenes may provide a convenient form for the generation of transgenic mice by cosmid-based rather than YAC-based technology. We have used the Fugu homologue of the HD gene to test this possibility.
It was difficult to predict whether the Fugu promoter would be functional in mouse cells. The Fugu and human 5′ UTR sequences are 46% identical at the nucleotide level, and possible conserved regulatory sequences are not apparent (4). The human gene has a CpG island identified by a cluster of unmethylated rare cutter restriction sites located within exon 1, 60-220 bp upstream of the ATG initiation codon. Although there is a putative computer predicted CpG island in the Fugu sequence this is probably too far upstream of the first exon, located at 2.7-2.8 kb before the ATG. Other possible CpG islands lie within the gene, including one of >8 kb. However, this elevated CG ratio could be accounted for by the Fugu codon preference in the exon-rich regions (4) . Comparison of human and mouse upstream sequences has uncovered a region of 150 bp of 78% identity (30) , but this region is not well conserved in Fugu, with the exception of a 28 nt stretch of 71% identity which spans the proposed transcription start site (4) . Similarly, potential SP1 and AP2 binding sites conserved between human and mouse (30) were not found in Fugu, suggesting that either they may not be involved in the regulation of HD, or that the Fugu and mammalian promoters are different. However, despite the apparent absence of conserved regulatory sequences, the FrHD gene was transcribed from its own promoter both in L-cell transfectants and in vivo in a transgenic mouse assay. This suggests sufficient conservation of unidentified transcription factor binding sites or of structural motifs to allow mouse transcription factors to direct expression of the Fugu gene.
In human there are two differentially polyadenylated isoforms of the HD mRNA generating 3′ untranslated regions of 600 and 3921 bp which Northern analysis suggests show a tissue-specific relative abundance (12, 14) . Although two transcripts are also detected on mouse Northern blots, probably resulting from alternative polyadenylation signals, cDNA clones containing the longer of the 3′ untranslated regions have not been identified (26, 27) . The FrHD sequence predicted three possible polyadenylation signals at positions 26080 (AGTAAA), 26884 (AGTAAA) and 27410 (ATTAAA). The 26884 signal is preceded by a 45 bp region that has 69% identity to the human sequence, which is also the most conserved region between the mouse and human 3′ untranslated regions (4) . Using 3′ RACE we were able to identify transcripts with polyA tails arising from signals at positions 26080 and 27410, but not from 26884. Therefore, the functional significance of the sequence conservation preceding 26884 is not clear. It is interesting that the human, mouse and Fugu genes all appear to have two polyadenylated forms, and that the FrHD mRNA was polyadenylated in mouse as in Fugu tissues. The 3′ untranslated regions in Fugu are of 191 and 1521 bp, compared with 600 and 3921 bp in human.
Although the FrHD gene was found to be expressed from its own promoter in mouse cells and polyadenylation was conserved, we found multiple instances of aberrant splicing throughout the mRNA. In metazoans, high fidelity in pre-mRNA splicing is important at three distinct points during the splicing pathway: first during the initial recognition of the 5′ and 3′ splice site; second for connecting the correct pairs of 5′ and 3′ splice sites across the intron; and third for selecting the precise bonds for cleavage at each 5′ and 3′ splice site. The cis-acting sequences in the pre-mRNA that participate in the initial complex formation are localized to a ∼300 nucleotide region containing the branchpoint sequence (BPS), the 3′ splice site, the exon and the 5′ splice site, and it is the spacing of each of these elements within the 300 nucleotide region that determines whether complex assembly will occur. This model suggests that cryptic splice sites are not recognised because they are not situated at the appropriate distances from the multiple elements involved in efficient complex assembly (31) .
Prior to studying the processing of the Fugu pre-mRNA transcript in mouse cells, we used RT-PCR to test whether the Fugu pre-mRNA was processed in Fugu tissues as predicted from the comparison of the human and Fugu genes. Amplification products of the predicted size were obtained across the entire gene except in three regions. The retention of intron 7 and the use of an internal splice acceptor in intron 63 maintains the reading frame of the message. All tissues contained both the intron 7 spliced and non-spliced isoforms. However, only brain contained both of the intron 63 isoforms, all other tissues tested containing only the alternatively spliced version. The identification in Fugu tissues of the incorrectly spliced isoform that has skipped exon 10 and retains intron 11 was unexpected, as this contains in-frame stop codons and is incompatible with the production of a full length protein. Not surprisingly, all tissues were also found to contain the correctly spliced version.
The expression analysis of the FrHD transfectants and transgenes would suggest that Fugu genes are unlikely to be useful in the construction of transgenic mice. The reduction of intron size appears severely to stress the fidelity of the mouse splicing machinery. The Fugu splicing complexes must have evolved in parallel to compensate for a reduction in the spacing of the cis-elements important for complex assembly. The identification of at least one aberrant splice form which would terminate the FrHD protein relatively close to its N-terminus suggests that the reduction in the size of the FrHD gene may have reached an equilibrium. The selective pressures causing the Fugu genome to lose DNA are not known. However, it is possible that the inability correctly to process pre-mRNAs once intron size has decreased beyond a certain threshold size acts as a counter selection to this DNA loss.
MATERIALS AND METHODS
Generation and characterisation of L-cell transfectants and transgenic mice
Mouse L-cells were co-transfected with 25 µg of the 30 kb EagI fragment containing the FrHD gene and 1 µg of the PGK-neo plasmid pKJ1 per 2.5 × 10 7 cells by calcium phosphate precipitation as previously described (32) . G418 resistant colonies were picked, expanded as stable transfectants and DNA was prepared. Southern blotting was to nylon membranes (Merck) and hybridisations were performed as previously described (33) . Southern blots of HindIII and EcoRI digested DNA probed with F36Eag30 were indicative of intact FrHD integrants and BamHI Southerns probed with F64H2.8 were used to show that the promoter region was present. DNA for transgenesis was purified from agarose by Biotrap (Schleicher and Schuell), resuspended in TE 0.1 and injected into fertilised mouse embryos at a concentration of 5 ng/µl by standard procedures (34) . Genotyping of mice was performed on DNA prepared from tail biopsy (34) by both Southern blotting (F36Eag30 as hybridisation probe) and PCR. Amplification was using primers 40022 and 40028 (Table 1) 
Expression analysis
RNA was prepared from cell lines and tissues as described (35) . Northern blots contained 20 µg total RNA per lane and hybridisations were as previously described (33) . RNA was reverse transcribed (14 U/µl MMTV RTase, BRL) in 50 mM KCl, 10 mM Tris-HCl pH 9.0, 0.1% Triton X-100, 6.5 mM MgCl 2 , 10 mM DTT, 1 mM dNTPs, 10 ng/µl random hexamers with 0.35 U/µl RNasin (Promega) at 10 min at 23_C and then 40 min at 37_C. Primers were selected from those presented in Table 1 and PCR was performed as above except in the case of the reaction containing primers 40043 and 45301, to which no DMSO was added. Southern blots of PCR products were hybridised with oligonucleotides as previously reported (36) . 3′ RACE reactions were carried out as described by Frohman (37) using the nested internal primers listed in Table 1: 46853 and 45308; 40051 and 40058; 40050 and 40059. Reverse transcription [using the QT primer (37)] and PCR were performed using the parameters described above.
DNA sequencing
PCR products were either blunt ended by T4 DNA polymerase (NEB) as recommended by the manufacturer at 12_C for 25 min, and subcloned into SmaI cut bluescript plasmid (Stratagene) after the addition of 5′ phosphates using T4 DNA kinase (NEB), or purified by Geneclean (Bio 101 Inc.) and sequenced directly. Sequencing was by dideoxy chain termination (38) using an automated gel reader (377, Applied Biosystems).
